IBD biological therapy audit

The biological therapy audit's aim is to measure the efficacy, safety and appropriate use of biological therapies (Infliximab and Adalimumab) in patients with inflammatory bowel disease in the UK.

What we are doing

The audit aims to assess nationally:

  • the appropriate use / prescribing of biological therapies (Adalimumab and Infliximab) in the treatment of IBD
  • the efficacy of biological therapies in the treatment of IBD
  • the safety of biological therapies in the treatment of IBD
  • IBD patients' views on their quality of life at defined intervals throughout their use of biological therapies.

What we have produced

The National clinical audit of biological therapies – Annual report 2016 is the fifth report of the biological therapy element of the UK IBD audit and has been designed to measure the efficacy, safety and appropriate use of biological therapies in patients with IBD in the UK.
The fourth biological IBD audit measures the efficacy, safety and appropriate use of anti-TNFα drugs in patients with IBD in the UK.
The fourth biological IBD audit measures the efficacy, safety and appropriate use of anti-TNFα drugs in patients with IBD in the UK.
This report analysis includes those patients who were newly started on biological therapies between 12 September 2011 and 28 February 2014
This report publishes national‐ and hospital‐level findings on the efficacy, safety and appropriate use of biological therapies.
The first full national report of the biological therapy element of the UK IBD audit.
The analyses within this report include only patients that were newly started on biological therapies between 12 September 2011 and 28 February 2013.
This interim data quality report is to inform the IBD community of the ongoing progress and development of the biologics audit.